 Cardiac toxicity years anthracycline therapy cardiac status long-term survivors pediatric malignancies chemotherapy anthracyclines DESIGN METHOD.-Patients echocardiogram years median years completion anthracyclines prospective retrospective analysis consecutive sample patients total anthracycline dose median patients mediastinal radiotherapy MAIN OUTCOME overall incidence severity abnormal systolic cardiac function entire cohort Risk factors total anthracycline dose mediastinal radiotherapy age treatment length follow-up Twenty-three percent cohort abnormal cardiac function noninvasive testing long-term follow-up Correlation total cumulative dose length follow-up mediastinal irradiation incidence abnormalities significant Fifty-six patients years median years median anthracycline dose Thirty-eight percent patients patients years abnormal findings Sixty-three percent patients years anthracyclines abnormal findings Nine patients late symptoms cardiac failure dysrhythmia patients Microscopic examination myocardium biopsy autopsy fibrosis incidence late cardiac abnormalities warrants evaluation patients anthracyclines patient care design future chemotherapeutic protocols